Michael Migden MD

Dr. Migden is Professor in the departments of Dermatology and Head and Neck at The University of Texas MD Anderson Cancer Center. He is a Mohs surgeon and cutaneous oncologist. His Mohs surgery practice includes removal of advanced surgically resectable tumors, immunohistochemistry on Mohs frozen sections, and advanced reconstruction of larger and complex defects. His research roles include that of global study PI, steering committee chair, and consultant for multiple clinical trials in basal and squamous cell carcinoma including trials of hedgehog inhibitors, checkpoint inhibitors and genetically modified oncolytic viruses. He was a lead U.S. enroller and first author in publications for the trials bringing cemiplimab, and hedgehog inhibitors to FDA approval. His research has been published in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology as well as other peer-reviewed journals. He is the editor/author of the only modern book on basal cell carcinoma, mutliple book chapters and has spoken nationally and internationally on cutaneous reconstruction, hedgehog inhibitor therapy, immunotherapy, oncolytic viruses, intratumoral delivery of cancer therapy.